Adherium wins approval to sell its 'smart' inhaler devices in Canada

Australia's Adherium Group announced clearance to sell its SmartTurbo and SmartTouch "smart inhaler" devices in Canada. They improve adherence by tracking usage and sending reminders. The SmartTurbo is used with AstraZeneca's ($AZN) Symbicort Turbuhaler and the SmartTouch works with a variety of metered dose inhalers, including those made by GlaxoSmithKline ($GSK). Adherium Group CEO Garth Sutherland said, "We are committed to ensuring our devices, which are proven to significantly improve the quality of life for people with respiratory diseases, are able to be supplied into all the major markets of the world. This clearance to market allows us to add Canada to the international markets which we already supply, including the US, Europe, China, Australia and New Zealand." Release

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…